1 / 17

My unique single-domain antibodies

Johannes Passecker 05.02.08. My unique single-domain antibodies. Antibodies. 5 classes of immunoglobins ~ 150 kilo Dalton (kDa) in size Main structure is very conserved: two identical 50kD heavy chains two 25kD light chains. Classes of antibodies. IgD found on B-cells

shadi
Download Presentation

My unique single-domain antibodies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Johannes Passecker 05.02.08 My unique single-domain antibodies

  2. Antibodies • 5 classes of immunoglobins • ~ 150 kilo Dalton (kDa) in size • Main structure is very conserved: • two identical 50kD heavy chains • two 25kD light chains

  3. Classes of antibodies IgD found on B-cells IgE binds to allergens IgG fight against invading pathogens Able to cross placenta IgA mostly in mucosal areas IgM - found on the surface of B cells eliminates pathogens in early humoral immune response Monomer (IgD, IgE, IgG) Dimer (IgA) Pentamer (IgM)

  4. Binding sites Where are my sleeping pills? • hypervariable regions (HV) • HV1, HV2 and HV3 • hypervariable loops of the HV regions (also called complementary determining regions or CDR ) • Binds the antigens by electrostatic and hydrophobic interactions, hydrogen bonds and Van der Waals forces

  5. Another class of ABs • Tylopoda species have however different antibodies in their serum • Camelidae family • Lamini and the Camelini genus • The dromedar and the two-hump camel Naturally occurring antibodies devoid of light chains , Hamers-Casterman C. Et al. , Nature. 1993 Unique single-domain antigen binding fragments derived from naturally occurring camel heavychain antibodies, Serge Muyldermans and Marc Lauwereys, J. of Mol. Recognition, 1999

  6. Heavy Chain Antibodies • No light chains • VHH domain of heavy chain ~ 15 kDa • Only 3 CDRs instead of 6 • Longer 3rd HV loop • more resistant to heat and pH E. De Genst et al. / Developmental and Comparative Immunology 30 (2006) 187–198

  7. Production of Nanobodies • Immunization of camelids with Freunds adjuvant • serum is fractionated by the use of protein G and A columns • Selection of VHH by two-step PCR and agarose gel seperation • PCR fragments are ligated into a phage display vector and transformed into an expression host • Expression of VHH domains by the host E. De Genst et al. / Developmental and Comparative Immunology 30 (2006) 187–198

  8. Benefits of Nanobodies • a smaller size (MW of 15,000 instead of 30,000 for a scFv) • a good expression level in bacteria or yeast • a good specificity and affinity for the antigen • a higher thermo and chemical stability than corresponding Fv derivatives • a strictly monomeric behaviour

  9. Applications Buy shares of Ablynx • For use in affinity chromatography • Protection against virus infections • Detection of cell architecture and dynamics and non-invasive imaging for early detection of diseases e.g. Alzheimer D. • Better suited as enzyme inhibitor than regular Fv domains • Useful for treatments of many diseases – most progressed teatments against – Thrombosis and Athritis • Use in Anti-venom treatment • Main patent holder: Ablynx, Belgium IPO in Nov. 2007

  10. Short Reminder – the AD Hypothesis http://www.alzforum.org/res/adh/cur/knowntheamyloidcascade.asp - Author: Dennis Selkoe

  11. 2 approaches for Treatment of AD • Inhibition of Aβ aggregate formation • Passive immunization therapy

  12. AD Treatment Pipeline • Bapineuzumab (Humanized mAB against Aβ) • Wyeth and Elan (Phase III started in 2007, Phase II not finished!!) • Alzhemed™ ( designed to cross the blood-brain barrier and inhibit Aβ formation) • Neuochem Inc. (considered to be failed in Phase III) • Flurizan™ (γ-secretase activity modulator) • Myriad Inc. (start of Phase III early 2007) • LY450139 (γ-secretase inhibitor) • Eli Lilly (Phase III clinical trials started mid 2007)

  13. A camelid antibody fragment inhibitsthe formation of amyloid fibrils byhuman lysozyme • VHH domain raised against wild-type human lysozyme inhibits the in vitro aggregation of its amyloidogenic variant • transmission of long-range conformational effects • reducing the ability to form an amyloidogenic protein • effective method of preventing its aggregation -> Implications for AD or Parkinson Disease Aggregation of D67H lysozyme Blue: absence of AB Pink:presence of AB (1:0,5) Green: presence of AB (1:1) Red: wild type Lysozyme – non aggregated form Dumoulin M, et al. A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme, Nature. 2003 Aug 14;424(6950):783-8

  14. Passive Immunization • Active immunization – risk of meningitis • Passive Imm.: Antibodies capable of binding monomeric/low molecular weight forms of Aβ (in the periphery) or aggregated states of Aβ (in the brain) reduce the amyloid burden in animal studies Weiner HL, Frenkel D (2006) Nat Rev Immunol 6:404–416

  15. 3 hypothesis on how passive immunization in AD works • microglial activation • antibodies bind to amyloid plaques, triggering microglia activation and infiltration of tissue* • catalytic dissolution • Abs act as chaperones catalyzing the structural change of the Aβ peptide from the – β-strand to an alternative conformation less prone to aggregation ‡ * Schenk D et al. (1999) Nature 400:173–177. Bard F et al. (2000) Nat Med 6:916–919. ‡ Solomon B et al. (1997) Proc Natl Acad Sci USA 94:4109–4112.

  16. 3 hypothesis on how passive immunization in AD works (2) • the peripheral sink hypothesis • antibodies bind to Aβ in the bloodstream, shifting the distribution of Aβ between the brain and the peripheral circulatory system and thereby leading to a net efflux of Aβ from the central nervous system to plasma, where it is degraded DeMattos et al. (2001) Proc Natl Acad Sci USA 98:8850–8855.

More Related